Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. (ADVM): 3 pipeline candidates · ~3 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.0 months
D/E -2.30
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for Adverum Biotechnologies, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$28.0M
Quarterly Burn
$28.1M
Runway
3.0 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| ixo-vec | Phase 2 |
| Ixo-vec (formerly ADVM-022) | Phase 3 |
| ixoberogene soroparvovec (Ixo-vec; formerly ADVM-022) | Phase 3 |
Frequently asked questions
How many drug candidates are in Adverum Biotechnologies, Inc.'s pipeline?
Adverum Biotechnologies, Inc. (ADVM) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Adverum Biotechnologies, Inc.'s lead drug candidate?
Adverum Biotechnologies, Inc.'s most advanced tracked candidate is ixo-vec (Phase 2) for Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD; Neovascular Age-Related Macular Degeneration (nAMD).
What is Adverum Biotechnologies, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Adverum Biotechnologies, Inc. has approximately 3.0 months of cash runway.
Who is the CEO of Adverum Biotechnologies, Inc.?
Stockholders Laurent Fischer, M.D. is the chief executive officer of Adverum Biotechnologies, Inc. (ADVM).
Get the full picture on Adverum Biotechnologies, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.